Clinical Trial Update: 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma [Phase 2]

View source ↗

Summary

An update on an ongoing Phase 2 clinical trial evaluating 131I-Omburtamab for recurrent Medulloblastoma and recurrent Ependymoma. The trial is sponsored by the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ependymoma
• Medulloblastoma

Drugs mentioned

• 131I-omburtamab (omburtamab)

Snippet

Sponsor: Pediatric Brain Tumor Consortium | Conditions: Recurrent Medulloblastoma, Recurrent Ependymoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING